Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Cholargos – page 78

1 033 clinical trials in Cholargos, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Cholargos at a glance
1 033
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 033 trials in Cholargos

Open in trial search

Dry eye+1

Not recruiting

Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Rheumatoid arthritis

Not recruiting

Study Comparing Upadacitinib and Adalimumab for Adults with Moderate to Severe Rheumatoid Arthritis Not Responding to a Single TNF Inhibitor

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study Comparing Pembrolizumab Alone and with Sacituzumab Govitecan for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Colitis ulcerative

Not recruiting

Study on Upadacitinib for Children with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Ropeginterferon Alfa-2b for Patients with Essential Thrombocythemia Intolerant or Refractory to Other Treatments

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Ropeginterferon ALFA-2B
  • Sponsor:Aop Orphan Pharmaceuticals GmbH

Study of Belzutifan and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Deep vein thrombosis+1

Not recruiting

Study on the Effectiveness and Safety of BAY 3018250 and Low Molecular Weight Heparin for Patients with Proximal Deep Vein Thrombosis

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:BAY 3018250
  • Sponsor:Bayer AG

Dermatitis atopic

Not recruiting

Study of Upadacitinib for Adolescents and Adults with Moderate to Severe Eczema

Investigational
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Long-Term Study on Aflibercept for Retinopathy of Prematurity in Infants

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Aflibercept
  • Sponsor:Bayer AG

Study of Romiplostim Treatment for Chemotherapy-induced Low Blood Platelets in Adults with Gastrointestinal, Pancreatic, or Colorectal Cancer Receiving Oxaliplatin Chemotherapy

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Romiplostim
  • Sponsor:Amgen Inc.

Plasma cell myeloma

Not recruiting

Study of Daratumumab Injection for Patients with High-Risk Smoldering Multiple Myeloma

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Hodgkin's disease

Not recruiting

Study of Pembrolizumab with Chemotherapy for Children and Young Adults with Classical Hodgkin Lymphoma Not Responding Well to Initial Treatment

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years
  • Substances:Bleomycin
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Greece

The busiest research cities in the country

All 48 cities in Greece

Clinical research in Cholargos

What the registry says about research in the country

01 Lung Cancer Research

Comprehensive studies evaluating novel treatments for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), including investigations of targeted therapies and immunotherapy combinations.

  • Advanced treatment comparisons
  • Therapy combinations evaluation
  • Metastatic disease management

Research focuses on improving survival rates and treatment effectiveness for patients with various stages of lung cancer.

02 Breast Cancer Studies

Innovative clinical trials examining treatments for HER2-positive and estrogen receptor-positive breast cancer, with particular attention to early-stage and metastatic conditions.

  • Targeted therapeutic approaches
  • Hormone therapy evaluation
  • Recurrence prevention

Studies aim to enhance treatment outcomes and reduce recurrence risks in breast cancer patients.

03 Urological Cancers

Advanced research into bladder cancer and metastatic prostate cancer, exploring innovative combination therapies and novel treatment approaches.

  • Immunotherapy combinations
  • Treatment resistance studies
  • Novel drug evaluations

Trials focus on improving treatment outcomes for patients with advanced urological malignancies.

04 Gastrointestinal Oncology

Studies investigating treatments for advanced colorectal cancer, particularly focusing on specific genetic mutations and targeted therapies.

  • Mutation-specific treatments
  • Combination therapy assessment
  • Advanced disease management

Research aims to develop personalized treatment approaches based on genetic profiles.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.